Biphenyl as a Privileged Structure in Medicinal Chemistry: Advances in Anti-Infective Drug Discovery
Molecules · 2026
DOI: 10.3390/molecules31071109 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2026. Verfasst von Marilia Oliva Gandi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas-ICB, Universidade Federal do Rio de Janeiro-UFRJ, Rio…. Hauptthemen laut MEDLINE: Drug Discovery, Biphenyl Compounds, Anti-Infective Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeicoamento de Pessoal de Nível Superior, FAPERJ, National Council for Scientific and Technological Development.
Abstract (Originalsprache)
The discovery of novel anti-infective agents is a continuous challenge in medicinal chemistry, particularly due to the rise in resistant fungal and viral strains. Within this context, the biphenyl subunit has been identified as a highly versatile privileged structure capable of interacting with diverse protein targets via hydrophobic and π-interactions. The purpose of this study is to review the pharmacological potential of biphenyl-based compounds, focusing on their application as anti-infective agents. We comprehensively analyzed recent literature and rational design strategies concerning biphenyl derivatives, examining structure-activity relationships, molecular docking insights, and structural optimizations aimed at enhancing both pharmacodynamics and pharmacokinetics. The reviewed studies demonstrate that incorporating biphenyl moieties yields compounds with potent antifungal and antiviral activities. Specifically, optimized biphenyl derivatives exhibit strong inhibitory effects against resistant Candida strains and crucial viral targets, including mutant variants of the HIV-1 reverse transcriptase and protease enzymes. Furthermore, strategic modifications, such as scaffold hopping and the introduction of specific substituents, successfully mitigated cytotoxicity and improved metabolic stability against cytochrome P450 enzymes. Biphenyl serves as a robust and adaptable scaffold for drug design. Its rational structural optimization provides a viable pathway to overcome drug resistance and develop effective, metabolically stable anti-infective therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas-ICB, Universidade Federal do Rio de Janeiro-UFRJ, Rio de Janeiro 21941-902, Brazil.
- Laboratório de Síntese de Fármacos-LASFAR, Departamento de Síntese de Fármacos e Bioativos-DSFB, Instituto de Tecnologia em Fármacos-Farmanguinhos, Fundação Oswaldo Cruz-Fiocruz, Rio de Janeiro 21041-250, Brazil.
ORCID-Profile: Rodolfo Rodrigo Florido França, Nubia Boechat
Förderung
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- FAPERJ
- National Council for Scientific and Technological Development
- Coordination of Superior Level Staff Improvement
Zitieren
APA
Gandi, M. O., França, R. R. F., Castelo-Branco, F. S., & Boechat, N. (2026). Biphenyl as a Privileged Structure in Medicinal Chemistry: Advances in Anti-Infective Drug Discovery. Molecules. https://doi.org/10.3390/molecules31071109
Vancouver
Gandi MO, França RRF, Castelo-Branco FS, Boechat N. Biphenyl as a Privileged Structure in Medicinal Chemistry: Advances in Anti-Infective Drug Discovery. Molecules. 2026. doi:10.3390/molecules31071109
BibTeX
@article{Gandi2026,
author = {Gandi, Marilia Oliva and França, Rodolfo Rodrigo Florido and Castelo-Branco, Frederico Silva and Boechat, Nubia},
title = {Biphenyl as a Privileged Structure in Medicinal Chemistry: Advances in Anti-Infective Drug Discovery},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31071109}
}
EUVIMED